BioInvent International AB in March struck a deal with Bayer HealthCare related to the discovery and development of antibody products under which Bayer will have a non-exclusive research license for the use of BioInvent’s proprietary n-CoDeR library for the discovery of human monoclonal antibodies.
Earlier this month, the Immune Tolerance Institute Inc. (ITI) announced that Aaron B. Kantor, Ph.D. has joined the company in the position of chief scientific officer, reporting to Louis A. Matis, M.D., president and CEO.
QuantumBio Inc. recently netted a FastTrack Small Business Innovation Research Grant (SBIR) of more than $865,000 from the NIH for research and development of novel, quantum mechanics-based methodologies for protein/drug scoring and interaction decomposition to help better understand protein-drug interactions.
Hoping to set a new standard in cell culture study, WaferGen Biosystems Inc. announced six distributor agreements in as many weeks for the company’s SmartSlide Micro-Incubation System, a first-of-its kind family of integrated fluidics exchange micro-incubation products.
Japanese pharmaceutical research company Takeda Pharmaceutical Co. Ltd. has joined BG Medicine, Merck, AstraZeneca and Philips as the newest member of the High-Risk Plaque (HRP) Initiative, a pre-competitive industry collaboration working to reduce morbidity, mortality and costs associated with cardiovascular disease.
With plans to offer a comprehensive suite of outsourcing services to the global pharmaceutical industry, Commonwealth Biotechnologies Inc. (CBI), a provider of research and development products and services to the life sciences industry, has formed a joint venture with Venturepharm Laboratories Ltd. (VPL), a publicly-listed pharmaceutical research service company in Beijing, China.
I’m not ashamed to say that in the last hour I pumped roughly 200 mg of my favorite drug into my body in an attempt to be ready, focused and able to produce an editorial that is, if not entertaining, at least cogent.